Boehringer Ingelheim has over 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Check here for more information about www.boehringer-ingelheim.com
At Endeavor BioMedicines, we are boldly pursuing development of transformational medicines that may restore hope for patients with intractable diseases. We are challenging the status quo and working to provide treatment outcomes that go beyond slowing disease progression and possibly reverse disease trajectory.
Check here for more information about www.endeavorbiomedicines.com
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Guided by science and our collective expertise, we work closely with patients to understand real-world challenges and develop meaningful solutions to meet their needs. This collaborative spirit extends across all teams, where diverse perspectives drive innovation.
Check here for more information about www.insmed.com
